Blum Kristie A
Division of Hematology, The Ohio State University, Columbus, OH.
Hematology Am Soc Hematol Educ Program. 2015;2015:82-91. doi: 10.1182/asheducation-2015.1.82.
With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor, idelalisib, in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), a number of new agents targeting the B-cell receptor (BCR) pathway are in clinical development. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. This review will summarize the current data with the use of single agent and combination therapy with BCR inhibitors in NHL. In addition, commonly encountered as well as serious toxicities and hypothesized resistance mechanisms will be discussed. Lastly, this review will examine the future of these agents and opportunities to maneuver them into the front-line setting in selected NHL subtypes.
随着布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼以及磷酸肌醇-3-激酶（PI3K）抑制剂idelalisib在复发或难治性非霍奇金淋巴瘤（NHL）患者治疗中取得的近期成功，一些靶向B细胞受体（BCR）通路的新型药物正处于临床开发阶段。此外，多项将这些药物与传统细胞毒性化疗、免疫调节剂、单克隆抗体或其他激酶抑制剂联合使用的试验正在进行中。本综述将总结目前在NHL中使用BCR抑制剂进行单药治疗和联合治疗的数据。此外，还将讨论常见及严重毒性以及推测的耐药机制。最后，本综述将探讨这些药物的未来发展以及将它们应用于特定NHL亚型一线治疗的机会。
